BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 38309569)

  • 1. Antibody Profiling of Pan-Cancer Viral Proteome Reveals Biomarkers for Nasopharyngeal Carcinoma Diagnosis and Prognosis.
    Liang T; Chen H; Liu L; Zheng Y; Ma Z; Min L; Zhang J; Wu L; Ma J; Liu Z; Zhang Q; Luo K; Hu D; Ji T; Yu X
    Mol Cell Proteomics; 2024 Mar; 23(3):100729. PubMed ID: 38309569
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Establishment of VCA and EBNA1 IgA-based combination by enzyme-linked immunosorbent assay as preferred screening method for nasopharyngeal carcinoma: a two-stage design with a preliminary performance study and a mass screening in southern China.
    Liu Y; Huang Q; Liu W; Liu Q; Jia W; Chang E; Chen F; Liu Z; Guo X; Mo H; Chen J; Rao D; Ye W; Cao S; Hong M
    Int J Cancer; 2012 Jul; 131(2):406-16. PubMed ID: 21866545
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Single-assay combination of Epstein-Barr Virus (EBV) EBNA1- and viral capsid antigen-p18-derived synthetic peptides for measuring anti-EBV immunoglobulin G (IgG) and IgA antibody levels in sera from nasopharyngeal carcinoma patients: options for field screening.
    Fachiroh J; Paramita DK; Hariwiyanto B; Harijadi A; Dahlia HL; Indrasari SR; Kusumo H; Zeng YS; Schouten T; Mubarika S; Middeldorp JM
    J Clin Microbiol; 2006 Apr; 44(4):1459-67. PubMed ID: 16597877
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of Epstein-Barr Virus Serological Tools for the Screening and Risk Assessment of Nasopharyngeal Carcinoma: a Large Population-based Study.
    Guo J; Cui Z; Zheng Y; Li X; Chen Y
    Pathol Oncol Res; 2020 Oct; 26(4):2185-2190. PubMed ID: 32222897
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Significance of specific Epstein-Barr virus IgA and elevated IgG antibodies to viral capsid antigens in nasopharyngeal carcinoma patients.
    Hadar T; Rahima M; Kahan E; Sidi J; Rakowsky E; Sarov B; Sarov I
    J Med Virol; 1986 Dec; 20(4):329-39. PubMed ID: 3025351
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A Randomized Controlled Trial on Evaluation of Plasma Epstein-Barr Virus Biomarker for Early Diagnosis in Patients With Nasopharyngeal Carcinoma.
    Liu W; Li H; Sheng H; Liu X; Chi P; Wang X; Mao M
    Adv Ther; 2020 Oct; 37(10):4280-4290. PubMed ID: 32780356
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Significance of plasma IgA and IgG antibodies to Epstein-Barr virus early and viral capsid antigens in Thai nasopharyngeal carcinoma.
    Tiwawech D; Srivatanakul P; Karaluk A; Ishida T
    Asian Pac J Cancer Prev; 2003; 4(2):113-8. PubMed ID: 12875623
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of plasma Epstein-Barr virus (EBV) DNA levels and serum EBV immunoglobulin A/virus capsid antigen antibody titers in patients with nasopharyngeal carcinoma.
    Shao JY; Li YH; Gao HY; Wu QL; Cui NJ; Zhang L; Cheng G; Hu LF; Ernberg I; Zeng YX
    Cancer; 2004 Mar; 100(6):1162-70. PubMed ID: 15022282
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Plasma Macrophage Migration Inhibitory Factor and CCL3 as Potential Biomarkers for Distinguishing Patients with Nasopharyngeal Carcinoma from High-Risk Individuals Who Have Positive Epstein-Barr Virus Capsid Antigen-Specific IgA.
    Xue N; Lin JH; Xing S; Liu D; Li SB; Lai YZ; Wang XP; Mao MJ; Zhong Q; Zeng MS; Liu WL
    Cancer Res Treat; 2019 Jan; 51(1):378-390. PubMed ID: 29807404
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Combined detection of Epstein-Barr virus antibodies for serodiagnosis of nasopharyngeal carcinoma].
    Cai YL; Zheng YM; Wang W; Wei Y; Shen XX; Cheng JR; Wu YS; Gao JQ; Zhong WM; Li J
    Nan Fang Yi Ke Da Xue Xue Bao; 2010 Dec; 30(12):2746-8. PubMed ID: 21177196
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Combining Epstein-Barr virus antibodies for early detection of nasopharyngeal carcinoma: A meta-analysis.
    Lian M
    Auris Nasus Larynx; 2023 Jun; 50(3):430-439. PubMed ID: 36241564
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Nasopharyngeal carcinoma patients from Norway show elevated Epstein-Barr virus IgA and IgG antibodies prior to diagnosis.
    Simon J; Brenner N; Reich S; Langseth H; Hansen BT; Ursin G; Ferreiro-Iglesias A; Brennan P; Kreimer AR; Johansson M; Pring M; Nygard M; Waterboer T
    Cancer Epidemiol; 2022 Apr; 77():102117. PubMed ID: 35121404
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A Distinct Anti-EBV DNase Profile in Patients with Undifferentiated Nasopharyngeal Carcinoma Compared to Classical Antigens.
    Melouli H; Khenchouche A; Taibi-Zidouni F; Salma D; Aoudia N; Djennaoui D; Sahraoui T; Benyahia S; El Kebir FZ
    Viruses; 2023 Oct; 15(11):. PubMed ID: 38005835
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Assessment of detection assays of Epstein-Barr viral Rta-IgG, VCA-IgA, EA-IgA and Epstein-Barr viral DNA at different clinical stages in the diagnosis of nasopharyngeal carcinoma].
    Luo YL; Chen H; Peng SG; Lin JH; Huang PY
    Zhonghua Yi Xue Za Zhi; 2013 Nov; 93(44):3516-9. PubMed ID: 24521892
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Diagnostic significance of combined detection of Epstein-Barr virus antibodies, VCA/IgA, EA/IgA, Rta/IgG and EBNA1/IgA for nasopharyngeal carcinoma.
    Cai YL; Li J; Lu AY; Zheng YM; Zhong WM; Wang W; Gao JQ; Zeng H; Cheng JR; Tang MZ
    Asian Pac J Cancer Prev; 2014; 15(5):2001-6. PubMed ID: 24716925
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The reliability of IgA antibody to Epstein-Barr virus (EBV) capsid antigen as a test for the diagnosis of nasopharyngeal carcinoma (NPC).
    Levine PH; Pearson GR; Armstrong M; Bengali Z; Berenberg J; Easton J; Goepfert H; Henle G; Henle W; Heffner D; Huang A; Hyams VJ; Lanier A; Neel HB; Pilch B; Pointek N; Taylor W; Terebelo H; Weiland L
    Cancer Detect Prev; 1981; 4(1-4):307-12. PubMed ID: 6299561
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Chemokine CCL27 is a novel plasma biomarker for identification the nasopharyngeal carcinoma patients from the Epstein-Barr virus capsid antigen-specific IgA seropositive population.
    Mao MJ; Xue N; Wang XP; Chi PD; Liu YJ; Huang Q; Dai SQ; Liu WL
    BMC Cancer; 2018 Jan; 18(1):9. PubMed ID: 29295705
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antibodies against Epstein-Barr virus gp78 antigen: a novel marker for serological diagnosis of nasopharyngeal carcinoma detected by xMAP technology.
    Gu AD; Xie YB; Mo HY; Jia WH; Li MY; Li M; Chen LZ; Feng QS; Liu Q; Qian CN; Zeng YX
    J Gen Virol; 2008 May; 89(Pt 5):1152-1158. PubMed ID: 18420792
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Improved accuracy of detection of nasopharyngeal carcinoma by combined application of circulating Epstein-Barr virus DNA and anti-Epstein-Barr viral capsid antigen IgA antibody.
    Leung SF; Tam JS; Chan AT; Zee B; Chan LY; Huang DP; Van Hasselt A; Johnson PJ; Lo YM
    Clin Chem; 2004 Feb; 50(2):339-45. PubMed ID: 14684618
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Identification of a Novel, EBV-Based Antibody Risk Stratification Signature for Early Detection of Nasopharyngeal Carcinoma in Taiwan.
    Coghill AE; Pfeiffer RM; Proietti C; Hsu WL; Chien YC; Lekieffre L; Krause L; Teng A; Pablo J; Yu KJ; Lou PJ; Wang CP; Liu Z; Chen CJ; Middeldorp J; Mulvenna J; Bethony J; Hildesheim A; Doolan DL
    Clin Cancer Res; 2018 Mar; 24(6):1305-1314. PubMed ID: 29301829
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.